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Evaluating Prospective Partners When Scaling
Your Digital Health Company (Part 1)
By Jake D. Gatof
Picture this: You have built a digital
health company that could revolutionize
healthcare delivery; upend diagnostic
processes; accelerate data analysis;
erase communication barriers between
providers, patients and other participants;
or perhaps replace entire medical records
systems. You’ve proven your technology’s
functionality, raised an angel round
of financing, created a pilot program,
or maybe already launched a limited
commercial deployment. Based on any
one of these scenarios, you’re ready to
scale your company.
But now your next step forward is to
evaluate prospective partners in the digital
health industry that would best help your
company, and you don’t know where
to start. The usual prospects—venture
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investment, strategic technology players,
payers, and providers—are unique entities
with different priorities. It’s also possible
participants from each type of prospect
would have views different from yours as to
the overall objective, whether that is to land
a unicorn valuation, procure deployment
in a major healthcare system, integrate
into a major tech platform, or overhaul the
healthcare technology infrastructure.

on venture investment and strategic
technology players. Part two, which will
appear in WSGR’s next Digital Health
Report, will focus on two other players—
the payers and providers.

You find a whiteboard and start making
notes, outlining potential advantages
and disadvantages of working with each
partner. Meanwhile, you’re also thinking
about other challenges that lie ahead,
like the payment and reimbursement
landscape, regulatory uncertainties, data
privacy concerns, and, of course, the
company’s significant capital needs.

Agility and Disruption: Placing the
daydreaming about unicorn-like valuations
aside momentarily, you and your team
agree that taking the traditional tech
start-up path of venture first may provide
you with the agility needed to overcome
an inflexible healthcare system status
quo. That has proven to be true in
other entrenched industries such as
transportation, communication, and
banking. A directed focus to bring a refined
and consumer-friendly product to market—
without being overly concerned about

This two-part article summarizes the key
considerations that you may help point
you to the right partner. Part one focuses

Partner Option 1: Venture
Investment
Opportunities and Limitations

(Continued on page 2)
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Evaluating Prospective Partners . . . (continued from page 1)
the burdens of existing infrastructure or
potentially lagging acceptance—is almost
as enticing as the capital. In an industry
synonymous with bureaucracy, there is a
certain upside to the maxim that’s wellknown in venture circles: to the question
of how you draw an owl: first, draw some
circles, second, draw the rest of the owl.
Core Competencies: Additionally, the
shift to value-based care throughout
the industry necessitates both (i)
efficiency as an operating principle and
(ii) a capacity to market to the public a
broader awareness of the factors which
constitute an individuals’ health. Because
strategic efficiency and marketing are both
commonly core skills that are demanded
of venture-backed start-ups (especially
where there has been a track record of
success with other non-healthcare B2C
technologies), there is significant appeal to
applying the same concepts to healthcare,
despite the complexity of the industry.
Healthcare Outsider: Of course, engaging
with venture does raise the question of
how to break through the healthcare
industry’s significant barriers to entry.
By itself, venture is not necessarily able
to either drive adoption of technology
by providers, or influence payer
perspectives on the reimbursement or
the “bundleability” of your technology
in their payment structure. In this
context it may seem difficult early on
to not have a commercial or industry
partner or champion. This also leads to
the risk of attracting significant capital
based on unproven potential, without
having been forced to observe the real
world application and acceptance of
the technology, which may lead to the
mismanagement of shareholder and
investor expectations.
Exit Pressures: Venture may also be the
instinctual first choice if you are looking
to stand alone and remain unhindered
by exclusive arrangements or obligations
to a certain provider or payer. But when
it comes to standing alone in the digital
health arena, it is worth noting that there
were no digital health IPOs in 2017
and only one in 2018: Chinese fitness

tracker and smartwatch maker, Huami,
raised $110 million in its IPO. While there
has been significant M&A activity and
consolidation, including some major
testaments to the digital health investment
hypothesis (e.g. Flatiron), a majority of
the exits were to strategic acquirers, not
financial acquirers. These market trends
suggest that a stand-alone commercial
path to an IPO may be less plausible for
Venture/
Financial
Investors

most digital health companies, and that
partnership and collaboration, even at the
point of exit, will remain a hallmark of the
industry for the foreseeable future.
Transactional Issues and Processes
Transactional Efficiency and Focus: A
benefit of venture investment, at least
relative to certain alternatives, is a
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certain predictability and transactional
efficiency. While there is the usual
negotiation of valuation, board seats,
liquidation preferences, and all the other
financing document requirements, certain
matters that may otherwise be at play
in a commercial deal or collaboration—
regulatory approvals; the co-ownership,
licensing, and co-development of
intellectual property; or the integration
into incumbent systems or existing
technological architecture—would be
tabled, at least temporarily.
Network and Preparedness: The ability
to bring in sophisticated capital in the
early growth stages, with limited backand-forth as to regulatory strategy or IP
crossover, is attractive. If the investor has
ample industry experience, they should
be able to provide introductions to other
partners, which helps create an important
bridge to end-users. However, venture
deals should contemplate, incentivize, and
be structured to anticipate strategic or
commercial engagements with technology
players, payers, or providers. Whether
factored into protective provisions,
milestone constructions, or other standard
deal terms, investors and founders should
facilitate future partnerships by including
flexibility deal documents in anticipation of
future collaborations.

Partner Option 2: Strategic
Technology Players
Opportunities and Limitations
Acknowledgement of Market Opportunity:
Here’s a new scenario. Hypothetically,
imagine your co-founder and CTO
previously worked at [insert FAANG+
technology company here] before joining
you at NewCo. She reminds the team that
her former employer may be interested in
a partnership or collaboration. You know
it’s no secret that many of the technology
giants, including her previous employer,
are interested in entering the healthcare
space, and that a complete technological
disruption of the healthcare status quo
would benefit an advanced technology
company like yours—not to mention the
value of partnering with a market-leading
technology giant.
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Existing Engagement with Providers and
Payers: You have also seen tech giants
seeking to integrate with healthcare
provider systems. The steps taken by
big tech signals what their future roles
may be in the healthcare space. It also
reveals the advantages that could be
derived from the exciting prospect of
partnering with tech company platforms
that have existing adoption among
providers. For example, as reported by
CNBC1, Apple Chief Operating Officer Jeff
Williams, has noted that “the willingness
of health care institutions to work with
Apple is a big deal, given the slow pace
of change in medicine relative to other
sectors...but what’s more important
about Apple’s moves into the space is
the mission behind it—view[ing] the future
as consumers owning their own health
data.” Google also recently launched
the Cloud Healthcare API, which allows
clinicians and researchers to collaborate
with consumers. There’s also exciting
collaborations among technology players.
For example Fitbit and Google announced
a partnership in April to develop new
consumer and enterprise digital health
solutions.
Core Competencies: Partnering with
an established technology company
with strategic interests may also help
your team develop the critical skills and
competencies digital health companies
need. Experience in areas like identitydriven solutions and systems (including
blockchain solutions), data security, and
privacy policies and related regulatory
schemes could result in novel iterations
of the technology and product, and
also could help the strategic technology
company involved deliver even greater
value.
Healthcare Outsider and Exclusivity:
Similar to what could transpire by
taking the venture investment path,
partnering with a technology leader,
instead of a healthcare industry player
could leave open the key questions of
healthcare stakeholder engagement,
including adoption and reimbursement.
Plus, collaborating and integrating with
specific technology players may limit
future partnership options. And finally, if

https://www.cnbc.com/2018/03/29/apple-health-records-product-expands-to-40-hospitals-implications.html

1

3

you continue engaged in technological
developments with a given big tech
partner, you will need to balance your
company’s commitment to the existing
partnership with the need for flexibility for
future uses and deployments.
Transactional Issues and Processes
Detailed IP Negotiations: Engaging with
a major technology player will inevitably
lead to nuanced and complex negotiations
around IP development, sharing, and
ownership; the related know-how; and
any related improvements. Whether in
the context of an investment or a more
comprehensive collaboration, negotiations
with large, sophisticated technology
companies may be uniquely challenging,
and could lead to resource imbalances
and deal leverage. Engagement with
certain strategic technology partners
also could prompt discussions of mostfavored-nation commercial terms,
or exclusivity for certain licenses or
improvements developed during—or
merely influenced by—the collaboration.
Special Strategic Rights: Strategic
investment by technology players
could also include related agreements
regarding special rights in the context
of an acquisition, including rights of first
offer/rights of first refusal, carve-outs from
typical drag-along obligations, nuanced
confidentiality-sharing provisions, and
acknowledgements of the strategic
technology company’s ability to engage
with other partners without restriction.
Back to your whiteboard diagram, which
is now starting to fill with marks and
notes in different colors, you’ve now
considered the first pair of prospective
partners—procuring venture investment
and collaborating with a strategic
technology player. Soon enough, you’ll
want to add even more marks and notes
to your diagram. In Part II of our twopart perspective, which we will publish
in WSGR’s next Digital Health Report,
we’ll discuss another pair of prospective
partners in the healthcare industry—
payers and providers.
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Investment Trends in a Maturing
Digital Health Market
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By Brian Appel
Record Funding Pace in a Robust
Ecosystem
The pace of investment in digital health
companies continues to increase following
a record-setting 2017, which saw more
than $11.7 billion of capital pour into the
sector across 833 deals.1 The torrid pace
continued in the first quarter of 2018, as
digital health companies closed on $2.8
billion of investment in 191 deals, making
it the biggest first quarter to date for the
sector, with 60 deals more than Q1 2017.2
The numbers reflect a continuing trend of
steady growth since 2011, with investors
becoming increasingly comfortable
making larger investments in digital health
companies as the sector matures.
While dollars invested in digital health in
the first quarter of 2018 roughly match
Q1 2017 numbers, if 2017’s blockbuster
$914 million GRAIL deal is excluded,
there would be approximately 47 percent

more investment in Q1 2018 compared
to Q1 2017. The year 2018 is not lacking
for megadeals either: the top ten digital
health deals in the first quarter all involved
fundraising in excess of $50 million,
constituting 42 percent of all dollars
invested in the sector, and included four
transactions surpassing $100 million.
This reflects a significantly increased pace
compared to 2017, which saw only eight
megadeals north of $100 million, and only
one such transaction (23andMe’s $250
million raise) occurring in the second half
of 2017.
The record pace of funding is related
to a greater number of maturing digital
health companies in search of larger
middle and late-stage financing rounds,
but also reflects an increased number of
active market participants. Data collected
by StartUp Health, which tracks venture
funding in the digital health sector, shows
that the first quarter of 2018 recorded
more repeat digital health investors than

ever before making a mix of new and
follow-on investments, with more unique
investors than in previous years. Forty
investors participated in more than one
digital health deal in the first quarter, with
33 of those participating in at least two
deals. Founders Fund, NEA, and Khosla
Ventures were the most active investors
in the sector in the first quarter, logging
five deals each. This was consistent with
year-end 2017 numbers reflecting Khosla
Ventures and Founders Fund along with
GE Ventures, Sequoia, and YCombinator
as the most active investors in the space.
A Maturing Market
Investment trends in 2017 and the
beginning of 2018 indicate that the digital
health sector continues to mature, with
significantly more deals occurring at
Series B and beyond. Year-end 2017
data from Startup Health indicates that
for the first time since the platform began
tracking digital health funding in 2010,
double-digit deal counts were recorded
at the Series B stage in each subsector
tracked, with the exception of education
and training. While most investment
activity in Q1 2018 was still concentrated
in early-stage deals, with Seed and
Series A deals accounting for 61 percent
of all first quarter deals, the number of
mid-stage and late-stage deals saw
increases as well. The average deal size
of late-stage Series D+ deals increased
by 60 percent in 2017, suggesting larger
follow-on investments and increased
investor comfort participating in larger
rounds for mature companies with proven
track records.3 This trend is consistent
with a broader shift in healthcare investing
towards expansion and later-stage deals.
According to PricewaterhouseCoopers,

 tartUp Health Insights Global Digital Health Funding Report – 2017 Year End Report. See: https://www.startuphealth.com/insights/
S
StartUp Health Insights Global Digital Health Funding Report 2018 Q1. See: https://www.startuphealth.com/insights/
3
RockHealth 2017 Year End Funding Report. See: https://rockhealth.com/reports/2017-year-end-funding-report-the-end-of-the-beginning-of-digital-health/
1
2

4
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middle and later-stage transactions made
up the majority of healthcare deals in the
first quarter of 2018, though unlike the
digital health sector, healthcare investing
generally saw ongoing declines in earlystage activity.4

the most dollars into companies focused
on biometric data acquisition ($537 million,
or 19.2 percent of the total dollars raised
in the quarter), clinical workflow ($472
million/16.8 percent), and administrative
workflow ($347 million/12.4 percent).

Certain subsectors within digital health
have seen greater investment in later-stage
financing rounds, with biometric data
acquisition, wellness, and personalized
health tallying the highest Q1 2018
numbers of mid-stage and late-stage
investments. Increased later-stage activity
in these subsectors is consistent with
the emphasis prior to 2016 on delivering
digital health solutions directly to the
consumer, while early-stage investment in
these areas has slowed as investors have
increasingly concentrated on providerfocused solutions.

However, digital health companies focused
on consumer health information accounted
for $1.6 billion of investment in 2017
(24.1 percent of all dollars invested in the
sector) across 41 deals (7 percent of the
total), suggesting that investors remained

Ongoing Shift to Provider Solutions
In the first quarter of 2018, digital health
companies offering provider-focused
solutions received the most capital in
financing rounds ($1.42 billion), accounting
for approximately 50.7 percent of the
total dollars invested in the sector. This
reflects an ongoing trend over the last
two years: as investors have shifted
from consumer wellness applications
to solutions delivering tangible clinical
impact, investment in monitoring, treating,
and diagnosing diseases has increased
significantly, as has investment in workflow
functions designed to make healthcare
practices more efficient. Strategic
investors, in particular, have shifted their
attention to clinically focused start-ups
as they begin to see how technologies
designed to affect patient behavior can
generate better health outcomes and cost
savings.5 In early 2018, investors poured

support raised $524 million, or 18.7
percent.
A Coming Uptick in Exit Activity?
The year 2017 saw no initial public
offerings in the digital health sector,
a somewhat surprising shift following
successful recent IPOs of digital health
pioneers like iRhythm and Teladoc.
Mergers and acquisitions represent the
other path for digital health liquidity events,
but according to a report on digital health
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convinced of the value proposition offered
by B2C companies. In the first quarter of
2018, digital health companies providing
a product or service to patients received
$949 million, or 33.9 percent of all dollars
invested in the space—second only to
provider-focused solutions. In terms of the
most popular use cases for digital health
technology in the first quarter of 2018,
genomics applications received $565
million, or 20.2 percent of total capital
raised in Q1; diagnostic/screening startups raised $539 million, or 19.3 percent;
and companies providing clinical decision

trends by CB Insights, the number of M&A
exits in the sector dropped significantly
to 132 in 2017, down from 145 deals in
2016.6 Over the last two years, digital
health M&A has been on the decline as a
result of increasing available private capital
(as detailed above), high valuations in
the sector, and tentativeness from likely
acquirers. According to data compiled by
Silicon Valley Bank, this trend is contrary
to patterns in other parts of the healthcare
market, where M&A activity remains
steady.7

PriceWaterhouseCoopers Healthcare MoneyTree Report Q1 2018. See: https://www.pwc.com/us/en/health-industries/publications/assets/pwc-healthcare-moneytree-report-q1-18.pdf
5
Silicon Valley Bank: Consumer Digital Health: How Market Shift Is Leading to New Opportunities. See: https://www.svb.com/digital-health-report/
6
CB Insights: 2018 Digital Health Trends. See: https://www.cbinsights.com/research/briefing/trends-in-digital-health-2018/
7
Silicon Valley Bank: Trends in Healthcare Investments and Exits 2018. See: https://www.svb.com/healthcare-investments-exits-report/
4
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Investment Trends in a Maturing Digital Health Market
However, a few factors suggest that 2018
and 2019 may see a reversal of the trend.
First, following the passage in late 2017
of federal tax reform legislation providing
for cash repatriation at reduced rates,
large tech and healthcare corporations
such as Apple, Microsoft, Pfizer, Johnson
& Johnson, and Merck are bringing
significant sums of money back to the
U.S. from overseas. While much of the
repatriated funds have been used for
stock repurchases and other purposes,
large corporates can put some of the
funds to work in mergers and acquisitions.
Second, with digital health companies
receiving more mid- and late-stage
investment in 2017 and 2018 as detailed
above, there may be increasing pressure
for exit activity throughout 2018 and into
2019.
Since 2015, companies focused on
enhancing electronic health record

(continued from page 5)

Digital health first exits, 2013 - 2017
functionality or improving
11
clinical workflow have been
8
the most popular acquisition
5
1
targets for healthcare
incumbents. According to
5
market analysis by CB Insights,
going forward in 2018, pharma
corporates could target digital
health companies to reach
99
138
160
145
132
consumers directly and find
2013
2014
2015
2016
2017
AI expertise; medical device
M&A
IPO
strategics could acquire digital
health companies for their
Source: CB Insights 2018 Digital Health Trends Report
expertise in software, user
experience and AI; while tech
the sector means more innovation in
companies, such as Apple,
all subverticals of digital health, and
Microsoft, and Amazon, could look at
no dearth of investment or acquisition
acquisitions to bolt on companies with
opportunities for potential acquirers
expertise in healthcare analytics and data
as they continue to make sense of the
sources.
space and understand how digital health
Whatever the case, the constant and
technologies fit within their existing
increasing flow of venture capital into
product or service offerings.

Software Components of Digital Health
Innovations Raise Unique Questions for
Standard University Technology Licenses
By Rachel Landy
Imagine you have spent your graduate
school years toiling away in a university
research lab developing a groundbreaking
digital health innovation. You and
another lab worker are convinced that
your latest discovery, a smart medical
device with embedded software that
connects to a mobile app, will forever
change diagnostics. Having developed
a prototype, including the embedded
software and mobile app, you decide
to form a company to commercialize
the product. You have heard that the
university will likely take ownership over

all of your intellectual property rights (you
do vaguely recall seeing something to that
effect in the paperwork you signed when
you first enrolled), but will grant you a
license on its standard terms so that you
may pursue your dreams.
You approach the university tech transfer
office to inquire about a license. You
thought you’d be able to sign it without
having to consult an attorney, but after
discussing the product with the licensing
officer, you become skeptical as the officer
focuses on ascribing an appropriate value
to the software code you have written
while at the same time mentioning that
6

most of the office’s deals don’t involve a
software component.
The line between life sciences (including
traditional medical devices) and software
companies has blurred in smart devices
and in the digital health space, and as
the officer indicated, many university
licenses—which historically focused on
patentable inventions—have failed to
catch up. Many provisions in the form
agreements that universities typically
provide are not applicable to software
licensing, resulting in far-reaching diligence
and commercialization issues. Below, we
highlight a few of the issues to address
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when your university license includes a
license to software.
1. L
 icense Rights. A typical university
license grant mirrors a standard patent
license grant, enumerating the rights
afforded to patent owners (to make,
have made, use, import, and offer for
sale). Software, however, is primarily
protected under copyright and
therefore, the grant of rights should
reflect the rights associated with a
work of authorship: to reproduce,
publicly display, publicly perform,
create derivative works, and distribute
to the public.
2. F
 ield of Use. A typical patent license
limits the licensee-company’s exercise
of the licensed patent rights to a
specified field of use. For example, a
licensee to a drug delivery technology
conceived in a research lab may
be limited to delivery of therapeutic
agents for purposes of cancer
treatment. In contrast, where licensed
software is incorporated into a larger
code base, it can be practically very
difficult for a licensee-company to
comply with field-of-use limitations that
a university may wish to impose, as
doing so would require the company
to segregate, track and otherwise
treat the licensed software code in its
code base separately from all other
portions of that code base. Making
the problem worse, it is not unusual
for a code from one product to find its
way into other company products.
3. S
 ublicensing Conditions. University
licenses often contain extensive
conditions on the licensee-company’s
ability to grant sublicenses. These
might include a requirement to
provide copies of sublicenses to the
university, taking on liability for acts
of sublicensees, and requiring each
sublicensee comply with the university
license. Such conditions can make
sense in a patent context, where
sublicenses are limited in number
and typically occur in connection with
transformative business transactions.
However, in the software context
(where each unit of product is sold
pursuant to an end user license), these
conditions are neither appropriate nor
scalable.
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4. E
 conomics. As noted above,
university agreements may not be
drafted in a way that recognizes the
unique role of a license in the overall
commercialization of software (as
opposed to products sold pursuant
to a patent license). This point is
particularly salient when reviewing
customary economic provisions in a
university license, which distinguish
between two different revenue
sources: (i) royalties paid on the
licensee-company’s unit sales of
products; and (ii) a percentage of
revenues the licensee-company
receives from sublicensees (referred to
as “sublicensing revenues”). There can
be a very significant difference in the
two rates, with the latter being higher
(most universities take the position that
they should receive 20-50 percent of
the sublicense revenues). A company
should consider the following when
negotiating these provisions:
		 a. Royalty rates are often set with the
underlying notion that an exclusive
patent license from the university
gives the licensee exclusivity in
the relevant market. However, that
same exclusivity does not attach in
a pure copyright license—a thirdparty developer could create the
same or similar functionality without
infringing the underlying copyright.
As a result, the rate should be
reduced to reflect the nature of the
rights granted.
		 b. Many ordinary course commercial
arrangements, such as “OEM”
distribution agreements pursuant to
which software code is incorporated
into a third party product, could
trigger a sublicensing revenue
share, as opposed to a lower
net sales royalty rate. Incurring
royalty obligations under the higher
sublicensing rate for these ordinary
course transactions is likely to be
commercially unworkable.
		 c. The company should ensure that
any ordinary course end user
licenses are subject to the unit sales
royalty rate and not the sublicensing
revenue rate, which is intended to
capture value unrelated to sale of
the underlying product.
7

5. R
 ights upon Termination. Upon
termination of a university license, a
patent licensee is usually prohibited
from exercising further rights and
may also be required to terminate all
sublicenses. Again, that construct
does not translate well to the
software for a number of reasons.
First, once software is incorporated
into a code base, it cannot easily be
replaced. Engineering snippets of
code out could require a significant
development expense. Second, once
a license is granted to a user, it often
cannot practically be terminated
(particularly if the software is made
available for download by customers).
Once the code is downloaded, the
company has no practical way to stop
the consumer from using the code.
6. U
 nited States Government Rights.
Under the Bayh-Dole Act (codified
at 35 U.S.C. Section 200–212, and
implemented by 37 C.F.R. 401), a
university that receives federal grant
funding may elect to take ownership
of patentable inventions made with
that funding, but in doing so becomes
subject to various restrictions. These
include retaining title to subject
inventions and requiring that unless
an exemption is obtained, all products
that embody that invention must be
manufactured substantially in the U.S.
Universities often include extensive
language regarding these terms in
license agreements, all of which are
largely inapplicable to copyright and,
by extension, software. These should
be deleted.
University licensing historically focused
on patents, and as a result, university
license agreements were drafted to apply
to patents. However, as digital health
becomes more prevalent, university
licenses will increasingly need to
contemplate software components and the
distinct legal landscape in which software
is licensed. Until then, licensing software
from universities will require significant
revisions to form license agreements.
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Medical Device Conference 2018
Join us at WSGR’s 26th Annual Medical Device Conference, which is
scheduled to be held on Thursday, June 21, and Friday, June 22. This
year’s Conference will focus on strategies that can help medtech startups address the challenges they face today. Top industry CEOs, venture
capitalists, industry strategists, investment bankers, and market analysts will
offer their insights and expertise in a series of panels and presentations.
To register, or for more information about speakers and program topics, visit
http://mdc.wsgrevents.com/.
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